Anti-Ganglioside GD2 Reference Antibody (Dinutuximab, RUO) (YP115016)

Name: Anti-Ganglioside GD2 Reference Antibody (Dinutuximab, RUO)
Brand: abinScience
SKU: YP115016
Price: 176 USD
Availability: InStock

Datasheet Share product Copy info

Price(USD):

Spec:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Number:

Get quote

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.

YP115016

Description

Dinutuximab (YP115016) is a research-grade recombinant antibody targeting Ganglioside GD2. Produced in mammalian cells with native-like glycosylation.

Highlights

●Research Grade — For PK/PD studies, assay development, and ADA research.
●Native Glycosylation — Mammalian expression ensures native-like patterns.

Species reactivity

General

Applications

ELISA, Bioactivity: FACS, Functional assay, Research in vivo

Host species

Chimeric

Isotype

IgG1-kappa

Expression system

Mammalian cells

Clonality

Monoclonal

Target

Ganglioside GD2

Endotoxin level

Please contact the lab for this information.

Purity

>95% purity as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

CAS: 65988-71-8

Form

Liquid

Storage buffer

0.01M PBS pH 7.4

Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Product Usage Information

Application	Dilution
ELISA	1:2000-1:20000

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Alternate Names

14.18, MAb-14.18, MOABCh14.18, CAS: 1363687-32-4, DGK07804

Background

Lorukafusp alfa (14.18 mAb; hu14.18-IL2) is an immunocytokine consisting of the humanized 14.18 anti-GD2 mAb linked to IL210. Lorukafusp alfa has activity mediated by activation of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity via the binding of hu14.18-IL2 to GD2 on the tumor cell surface, followed by binding to Fc receptors on effector cells along with activation of NK and T cells via IL2 receptor binding. Lorukafusp alfa has anti-tumor activity.
• Ganglioside GD2: a novel therapeutic target in triple-negative breast cancer., PMID:34596246
• GD2 is a Crucial Ganglioside in the Signal Modulation and Application as a Target of Cancer Therapeutics., PMID:39921214
• Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers., PMID:38593230
• Ganglioside GD2 Contributes to a Stem-Like Phenotype in Intrahepatic Cholangiocarcinoma., PMID:39726234
• Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma., PMID:33479234
• Ganglioside GD2 Enhances the Malignant Phenotypes of Melanoma Cells by Cooperating with Integrins., PMID:35008849
• RNA Sequencing-Based Identification of Ganglioside GD2-Positive Cancer Phenotype., PMID:32486168
• Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M⁺ diffuse midline gliomas., PMID:29662203
• Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma., PMID:20879881

Note

For research use only. Not suitable for clinical or therapeutic use.

Images